NCT02700100Unknown不适用
Prospective, Non-randomised, Open Label Clinical Study to Assess the Safety of the Bioabsorbable Pulmonary Valved Conduit (PV-001) in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction
Xeltis5 个研究点 分布在 3 个国家目标入组 12 人开始时间: 2016年6月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 12
- 试验地点
- 5
- 主要终点
- The survival rate of participants at 6 months following implantation of the Bioabsorbable Pulmonary Valved Conduit (PV-001),, measured by the fact that the patient is still alive at the time of the 6 month FU visit
研究概览
简要总结
The study is a prospective, non-randomised, open label clinical study to assess the safety of the Bioabsorbable Pulmonary Valved (PV) conduit (PV-001) in subjects > 2 years and < 22 years of age, undergoing Right Ventricular Outflow Tract (RVOT) reconstruction. It is a first in man feasibility study which will include 10-12 patients in up to 6 sites in Europe.
The primary objective of the study is to assess the survival rate of subjects at 6 months following implantation of the Bioabsorbable Pulmonary Valved Conduit (PV-001).
Secondary objectives:
- The survival rate of subjects at 12 months following implantation of the Bioabsorbable Pulmonary Valved Conduit (PV-001)
- The percentage of conduit failure at 6 months and 12 months, where conduit failure includes the need for reintervention or reoperation.
- The pressure gradient across the pulmonary valve will have an acceptable level at 12 months follow up.
- The pulmonary regurgitation measured will not exceed a moderate grading at 12 months follow up.
- To evaluate the usability of the Bioabsorbable Pulmonary Valved Conduit (PV-001) during the surgical procedure, using exploratory parameters
Long term safety will be assessed up to 60 months post implantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient requiring RVOT reconstruction, suitable for 16 mm or 18 mm conduit.
- •Male or Female.
- •Age > 2 years and < 22 years.
- •Right Ventricular to Pulmonary Artery peak gradient > 35mm Hg or moderate or severe Pulmonary Valve regurgitation (≥3+), or have both.
- •The patient, and the patient's parent / legal representative where appropriate, has been informed of the nature of the study, agrees to its provisions and has provided written informed consent by signing the approved informed consent form.
- •The patient, and the patient's parent / legal representative where appropriate, and the treating physician agree that the subject will return for all required post-procedure follow up visits and the subject will comply with protocol-required follow-up visits.
排除标准
- •Need for or presence of prosthetic valve at other position.
- •Need for concomitant surgical procedures (outside of the heart).
- •Patients with previously implanted pacemaker (including defibrillators), or mechanical valves.
- •Active infection requiring current antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics).
- •Active endocarditis.
- •Leukopenia.
- •Acute or chronic anaemia.
- •Thromocytopenia.
- •Severe chest wall deformity.
- •Right ventricular outflow tract aneurysm.
- •Known hypersensitivity to anticoagulants and antiplatelet drugs.
- •Immunocompromised patient defined as: autoimmune disease, patients receiving immunosuppressant drugs or immunostimulant drugs.
- •Need for emergency cardiac or vascular surgery or intervention.
- •Major or progressive non-cardiac disease (liver failure, renal failure, cancer) that has a life expectancy of less than one year.
- •Currently participating, or participated within the last 30 days, in an investigational drug or device study.
- •Alcohol or drug abuse as defined by DSM IV-TR criteria for substance abuse - this includes the illicit use of cannabis within the last 12 months.
- •Females who are sexually active and are not willing to use adequate contraceptive precautions for the next 2 years
- •Subject has medical, social or psychosocial factors that, in the opinion of the Investigator, could impact safety or compliance with study procedures.
结局指标
主要结局
The survival rate of participants at 6 months following implantation of the Bioabsorbable Pulmonary Valved Conduit (PV-001),, measured by the fact that the patient is still alive at the time of the 6 month FU visit
时间窗: 6 months
次要结局
- Overall satisfaction of the implantability of the Bioabsorbable Pulmonary Valved Conduit (PV-001), measured with a questionnaire given to the implanting surgeon at the time of implantation of the PV conduit (PV-001).(Intraoperative)
- The rate of patients with pulmonary regurgitation of equal or less than moderate at 12 months follow up, measured with echocardiography at 12 months follow up.(12 months)
- The survival rate of participants at 12 months following implantation of the Bioabsorbable Pulmonary Valved Conduit (PV-001), measured by the fact that the patient is still alive at the time of the 12 month FU visit.(12 months)
- The rate of reoperation or reintervention due to PV conduit failure at 6 months and 12 months follow up , measured by the fact that the patient did not have a reoperation or reintervention during the follow up time.(6 and 12 months)
- The rate of patients with a mean pressure gradient across the area of PV conduit implantation (RV to PA) of less than 40 mm Hg at 12 months follow up, measured with echocardiography at 12 months follow up.(12 months)
研究者
研究点 (5)
Loading locations...
相似试验
撤回
不适用
Xeltis Pulmonary Valved Conduit Safety and Performance StudyHeart Defects, CongenitalNCT03405636Xeltis
Enrolling By Invitation
不适用
Clinical Study to Evaluate the Efficacy and Safety of Matrix Pro TreatmentSkin LaxityWrinkleSkin ConditionNCT06726122Candela Corporation60
进行中（未招募）
1 期
A prospective, open label, non-randomised, clinical trial to determine if natalizumab (Tysabri) improves ambulatory measures in relapsing remitting multiple sclerosis (RRMS) patients. - TIMERMultiple sclerosisMedDRA version: 9.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2009-009503-19-BEBiogen Idec International GmbH200
已完成
不适用
Histological Study to Assess Safety and Efficacy of the TempSure Firm for Non-Invasive LipolysisNon-invasive LipolysisNCT04878172Cynosure, Inc.9
进行中（未招募）
不适用
Clinical Study to Evaluate the Safety and Efficacy of Candela TechnologyHair ReductionTattoo RemovalWrinkleScarsBenign Cutaneous Vascular LesionsSkin ConditionsAcneNCT06202274Candela Corporation500